

SENATE No. 1935

The Commonwealth of Massachusetts

—————
In the Year Two Thousand Thirteen
—————

SENATE, Thursday, November 21, 2013

The committee on Mental Health and Substance Abuse to whom was referred the petition (accompanied by bill, Senate, No. 919) of Michael O. Moore and Colleen M. Garry for legislation relative to synthetic marijuana reports the accompanying bill of the same title (Senate, No. 1935).

For the committee,
Joan B. Lovely

SENATE No. 1935

The Commonwealth of Massachusetts

In the Year Two Thousand Thirteen

An Act relative to synthetic marijuana.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 SECTION 1. Class C of section 31 of chapter 94C, as appearing in the 2010 Official
2 Edition, is hereby amended by inserting after subsection (e) the following subsection:-

3 (f) Unless specifically excepted or listed in another schedule, any material, compound,
4 mixture, or preparation, which contains any quantity of the following hallucinogenic substances,
5 or which contains any Cannabimimetic Agents that meet the criteria of any one or more of
6 paragraphs (a) through (t) and any substance within the structural classes identified below that is
7 a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and
8 functional assays:

9 (a) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the
10 phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.

11 (b) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole by substitution at the nitrogen
12 atom of the indole ring, whether or not further substituted on the indole ring to any extent,
13 whether or not substituted on the naphthoyl or naphthyl ring to any extent.

14 (c) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring,
15 whether or not further substituted in the indole ring to any extent, whether or not substituted on
16 the naphthoyl ring to any extent.

17 (d) 1-(1-naphthylmethyl)indene by substitution of the 3-position of the indene
18 ring, whether or not further substituted in the indene ring to any extent, whether or not
19 substituted on the naphthyl ring to any extent.

20 (e) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom
21 of the indole ring, whether or not further substituted in the indole ring to any extent, whether or
22 not substituted on the phenyl ring to any extent.

23 Such Cannabimimetic Agents include, but are not limited to:

24 (i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);

25 (ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
26 (cannabicyclohexanol or CP-47,497 C8-homolog);

27 (iii) 1-pentyl-3-(1-naphthoyl) indole (JWH-018 and AM678);

28 (iv) 1-butyl-3-(1-naphthoyl) indole (JWH-073);

29 (v) 1-hexyl-3-(1-naphthoyl) indole (JWH-019);

30 (vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole (JWH-200);

31 (vii) 1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250);

32 (viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)] indole (JWH-081);

33 (ix) 1-pentyl-3-(4-methyl-1-naphthoyl) indole (JWH-122);

34 (x) 1-pentyl-3-(4-chloro-1-naphthoyl) indole (JWH-398);

35 (xi) 1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM2201);

36 (xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl) indole (AM694);

37 (xiii) 1-pentyl-3-[(4-methoxy)-benzoyl] indole (SR-19 and RCS-4);

38 (xiv) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl) indole (SR-18 and RCS-8);

39 and

40 (xv) 1-pentyl-3-(2-chlorophenylacetyl) indole (JWH-203).